Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' innovative platform allows for the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering in one-step.
Products, services, technology
The resulting ADCs have a well-defined drug-to-antibody ratio, are stable and monomeric. All these favorable properties contribute to the high efficacy, stability and low level of toxicity observed so far. In summary, this approach enables the generation of ADC compounds for the treatment of patients with a high unmet medical need.
- https://www.ararisbiotech.com
- +41 44 633 24 37
- Send an email
